Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study

References

• Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, Shay DK, Marshfield G. Influenza Study, Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis. 2009;199(2):159–67. doi:10.1086/595861.
   PubMed Web of Science ®Google Scholar
• Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine. 2010;28(Suppl 4):D45–53. doi:10.1016/j.vaccine.2010.08.028.
   PubMed Web of Science ®Google Scholar
• Dunkle LM, Izikson R, Patriarca P, Goldenthal KL, Muse D, Callahan J, Cox MMJ, Team PSCS. Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older. N Engl J Med. 2017;376(25):2427–36. doi:10.1056/NEJMoa1608862.
   PubMed Web of Science ®Google Scholar
• Statler VA, Albano FR, Airey J, Sawlwin DC, Graves Jones A, Matassa V, Heijnen E, Edelman J, Marshall GS. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59months of age: a phase 3, randomized, noninferiority study. Vaccine. 2019;37(2):343–51. doi:10.1016/j.vaccine.2018.07.036.
   PubMed Web of Science ®Google Scholar
• Airey J, Albano FR, Sawlwin DC, Jones AG, Formica N, Matassa V, Leong J. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: a phase 3, randomized noninferiority study. Vaccine. 2017;35(20):2745–52. doi:10.1016/j.vaccine.2017.03.028.
   PubMed Web of Science ®Google Scholar
• Treanor JT, Albano FR, Sawlwin DC, Graves Jones A, Airey J, Formica N, Matassa V, Leong J. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: a phase 3, randomized noninferiority study. Vaccine. 2017;35(15):1856–64. doi:10.1016/j.vaccine.2017.02.066.
   PubMed Web of Science ®Google Scholar
• Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med. 2005;165:265–72.
   PubMed Web of Science ®Google Scholar
• Cassini A, Colzani E, Pini A, Mangen MJ, Plass D, McDonald SA, Maringhini G, van Lier A, Haagsma JA, Havelaar AH, et al., B.C. On Behalf Of The. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Euro Surveill. 2018;23(16). doi:10.2807/1560-7917.ES.2018.23.16.17-00454.
   PubMedGoogle Scholar
• Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, McLean HQ. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942–51. doi:10.1016/S1473-3099(16)00129-8.
   PubMed Web of Science ®Google Scholar
• Ng TWY, Cowling BJ, Gao HZ, Thompson MG. Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: a Systematic Review and Meta-analysis. J Infect Dis. 2019;219:1525–35.
   PubMed Web of Science ®Google Scholar
• N.M.P. Administration, Influenza Vaccine (Split Virion),Inactivated. http://app1.nmpa.gov.cn/data_nmpa/face3/base.jsp?tableId=25&tableName=TABLE25&title=%E5%9B%BD%E4%BA%A7%E8%8D%AF%E5%93%81&bcId=152904713761213296322795806604&CbSlDlH0=qAk7racmf3Kmf3KmfKJzH8SG.zGAeIHwe4nC9ZxjqRZqqEV. (Accessed July 7 2021).
   Google Scholar
• clinicaltrials, Influenza Vaccine (Split Virion) Inactivated, Quadrivalent. Hualan Biological Engineering. https://clinicaltrials.gov/ct2/show/NCT01511744?term=NCT01511744&draw=2&rank=1. ( Accessed July 7 2021).
   Google Scholar
• Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >/=18 years. BMC Infect Dis. 2013;13:343. doi:10.1186/1471-2334-13-343.
   PubMed Web of Science ®Google Scholar
• Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31(5):770–76. doi:10.1016/j.vaccine.2012.11.074.
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC. T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006;176(10):6333–39. doi:10.4049/jimmunol.176.10.6333.
   PubMed Web of Science ®Google Scholar
• U.S.F.a.D. Administration, Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-data-needed-support-licensure-seasonal-inactivated-influenza-vaccines. ( Accessed July 7 2021).
   Google Scholar
• DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635–45. doi:10.1056/NEJMoa1315727.
   PubMed Web of Science ®Google Scholar
• Pepin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. 2013;31(47):5572–78. doi:10.1016/j.vaccine.2013.08.069.
   PubMed Web of Science ®Google Scholar
• Bartoszko J, Loeb M. The burden of influenza in older adults: meeting the challenge. Aging Clin Exp Res. 2021;33(3):711–17. doi:10.1007/s40520-019-01279-3.
   PubMed Web of Science ®Google Scholar
• Wang Y, Cheng M, Wang S, Wu F, Yan Q, Yang Q, Li Y, Guo X, Fu C, Shi Y, et al. Vaccination coverage with the pneumococcal and influenza vaccine among persons with chronic diseases in Shanghai, China, 2017. BMC Public Health. 2020;20(1):359. doi:10.1186/s12889-020-8388-3.
   PubMed Web of Science ®Google Scholar
• Andrew MK, Bowles SK, Pawelec G, Haynes L, Kuchel GA, McNeil SA, McElhaney JE. Influenza Vaccination in Older Adults: recent Innovations and Practical Applications. Drugs Aging. 2019;36(1):29–37. doi:10.1007/s40266-018-0597-4.
   PubMed Web of Science ®Google Scholar
• Jiang M, Li P, Yao X, Hayat K, Gong Y, Zhu S, Peng J, Shi X, Pu Z, Huang Y, et al. Preference of influenza vaccination among the elderly population in Shaanxi province, China. Hum Vaccin Immunother. 2021;5:1–7. doi: 10.1080/21645515.2021.1913029.
   Web of Science ®Google Scholar
• Lau JTF, Ng CSM, Wu AMS, Ma YL, Lau MMC. Low coverage of influenza vaccination among Chinese children aged 12-23 months: prevalence and associated factors. PLoS One. 2018;13(10):e0205561. doi:10.1371/journal.pone.0205561.
   PubMed Web of Science ®Google Scholar
• Russell K, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, et al. Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. Vaccine. 2018;36(10):1272–78. doi:10.1016/j.vaccine.2018.01.045.
   PubMed Web of Science ®Google Scholar
• Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of Influenza Vaccine in the Community-Dwelling Elderly. N Engl J Med 2007;357(14):1373–81. doi: 10.1056/NEJMoa070844.
   Google Scholar